FDA Oks Novo Weekly Diabetes Injection

Dec 07, 2017

The FDA has approved Novo Nordisk’s Ozempic, a once-weekly injection for type 2 diabetes.

Ozempic consists of a weekly injection of semaglutide, which belongs to a type of drugs known as glucagon-like peptide 1 (GLP-1) receptor agonists.

In October, an FDA panel had voted unanimously in favor of the treatment. Trials included favorable head-to-head data against Eli Lilly’s rival drug, Trulicity, which is already on the market.

Analysts, using Thomson Reuters data, expect annual Ozempic, sales to reach $3.17 billion by 2023, with sales of Trulicity, rising to $3.71 billion.

Read the press release